Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Immuneering (IMRX) Operating Leases (2020 - 2024)

Immuneering has reported Operating Leases over the past 5 years, most recently at $3.9 million for Q3 2024.

  • Quarterly results put Operating Leases at $3.9 million for Q3 2024, down 7.66% from a year ago — trailing twelve months through Sep 2024 was $3.9 million (down 7.66% YoY), and the annual figure for FY2023 was $4.2 million, down 6.72%.
  • Operating Leases for Q3 2024 was $3.9 million at Immuneering, down from $4.3 million in the prior quarter.
  • Over the last five years, Operating Leases for IMRX hit a ceiling of $5.1 million in Q4 2021 and a floor of $481965.0 in Q3 2021.
  • Median Operating Leases over the past 5 years was $4.3 million (2024), compared with a mean of $3.6 million.
  • Peak annual rise in Operating Leases hit 842.53% in 2022, while the deepest fall reached 12.33% in 2022.
  • Immuneering's Operating Leases stood at $544767.0 in 2020, then skyrocketed by 834.51% to $5.1 million in 2021, then decreased by 12.33% to $4.5 million in 2022, then decreased by 6.72% to $4.2 million in 2023, then fell by 5.92% to $3.9 million in 2024.
  • The last three reported values for Operating Leases were $3.9 million (Q3 2024), $4.3 million (Q2 2024), and $4.4 million (Q1 2024) per Business Quant data.